12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

ATIR regulatory update

EMEA granted Orphan Drug designation to Kiadis' ATIR to prevent acute graft-versus-host disease (GvHD) following allogeneic bone...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >